natgillin/translations-raw huggingface dataset:
on the conclusion of the Protocol to the Partnership and Cooperation Agreement between the European Communities and their Member States, of the one part, and Ukraine, of the other part (PCA), on accession of the Czech Republic, the Republic of Estonia, the Republic of Cyprus, the Republic of Latvia, the Republic of Lithuania, the Republic of Hungary, the Republic of Malta, the Republic of Poland, the Republic of Slovenia and the Slovak Republic to the PCA and on adjustments to the PCA
o sklenitvi Protokola k Sporazumu o partnerstvu in sodelovanju med Evropskimi skupnostmi in njihovimi državami članicami na eni strani ter Ukrajino na drugi strani (SPS) o pristopu Češke republike, Republike Estonije, Republike Ciper, Republike Latvije, Republike Litve, Republike Madžarske, Republike Malte, Republike Poljske, Republike Slovenije in Slovaške republike k SPS in njegovim prilagoditvam
The Protocol to the Partnership and Cooperation Agreement between the European Communities and their Member States, of the one part, and Ukraine, of the other part (PCA), on accession of the Czech Republic, the Republic of Estonia, the Republic of Cyprus, the Republic of Latvia, the Republic of Lithuania, the Republic of Hungary, the Republic of Malta, the Republic of Poland, the Republic of Slovenia and the Slovak Republic to the PCA and on adjustments to the PCA, was signed on behalf of the European Community and the Member States on 29 April 2004 in accordance with Council Decision 2006/537/EC [2].
Protokol k Sporazumu o partnerstvu in sodelovanju med Evropskimi skupnostmi in njihovimi državami članicami na eni strani ter Ukrajino na drugi strani (SPS) o pristopu Češke republike, Republike Estonije, Republike Ciper, Republike Latvije, Republike Litve, Republike Madžarske, Republike Malte, Republike Poljske, Republike Slovenije in Slovaške republike k SPS in njegovim prilagoditvam je bil v imenu Evropske skupnosti in držav članic podpisan dne 29. aprila 2004, v skladu s Sklepom Sveta 2006/537/ES [2].
Pending its entry into force, the Protocol has been applied on a provisional basis from the date of accession.
Dokler ne začne veljati, se Protokol uporablja začasno od dne pristopa.
The Protocol to the Partnership and Cooperation Agreement between the European Communities and their Member States, of the one part, and Ukraine, of the other part (PCA), on accession of the Czech Republic, the Republic of Estonia, the Republic of Cyprus, the Republic of Latvia, the Republic of Lithuania, the Republic of Hungary, the Republic of Malta, the Republic of Poland, the Republic of Slovenia and the Slovak Republic to the PCA and on adjustments to the PCA is hereby approved on behalf of the European Community, the European Atomic Energy Community and the Member States.
Protokol k Sporazumu o partnerstvu in sodelovanju med Evropskimi skupnostmi in njihovimi državami članicami na eni strani ter Ukrajino na drugi strani (SPS) o pristopu Češke republike, Republike Estonije, Republike Ciper, Republike Latvije, Republike Litve, Republike Madžarske, Republike Malte, Republike Poljske, Republike Slovenije in Slovaške republike k SPS in njegovim prilagoditvam se odobri v imenu Evropske skupnosti, Evropske skupnosti za atomsko energijo in držav članic.
The text of the Protocol is attached to this Decision [3].
Besedilo Protokola je priloženo k temu sklepu [3].
The President of the Council shall, on behalf of the European Community and its Member States, give the notification provided for in Article 4 of the Protocol.
Predsednik Sveta v imenu Evropske skupnosti in njenih držav članic poda uradno obvestilo iz člena 4 Protokola.
The President of the Commission shall simultaneously give such notification on behalf of the European Atomic Energy Community.
Predsednik Komisije hkrati poda takšno uradno obvestilo v imenu Evropske skupnosti za atomsko energijo.
OJ C 174 E, 14.7.2005, p. 45.
UL C 174 E, 14.7.2005, str. 45.
See page 16 of this Official Journal.
Glej stran 16 tega Uradnega lista.
of 11 April 2006
z dne 11. aprila 2006
on the allocation of quantities of controlled substances allowed for essential uses in the Community in 2006 under Regulation (EC) No 2037/2000 of the European Parliament and of the Council
o dodelitvi količin nadzorovanih snovi, ki so dovoljene za uporabe bistvenega pomena v Skupnosti v letu 2006 v skladu z Uredbo (ES) št. 2037/2000 Evropskega parlamenta in Sveta
(notified under document number C(2006) 1483)
(notificirano pod dokumentarno številko C(2006) 1483)
(Only the Danish, Dutch, English, Estonian, Finnish, French, German, Italian, Slovenian, Spanish and Swedish texts are authentic)
(Besedilo v danskem, nizozemskem, angleškem, estonskem, finskem, francoskem, nemškem, italijanskem, slovenskem, španskem in švedskem jeziku je edino verodostojno)
Having regard to Regulation (EC) No 2037/2000 of the European Parliament and of the Council of 29 June 2000 on Substances that Deplete the Ozone Layer [1], and in particular Article 3(1) thereof,
ob upoštevanju Uredbe (ES) št. 2037/2000 Evropskega parlamenta in Sveta z dne 29. junija 2000 o snoveh, ki tanjšajo ozonski plašč [1], in zlasti člena 3(1) Uredbe,
The Community has already phased out the production and consumption of chlorofluorocarbons, other fully halogenated chlorofluorocarbons, halons, carbon tetrachloride, 1,1,1-trichloroethane, hydrobromofluorocarbon and bromochloromethane.
Skupnost je že postopno opustila proizvodnjo in porabo klorofluoroogljikovodikov, drugih popolnoma halogeniranih klorofluoroogljikovodikov, halonov, ogljikovega tetraklorida, 1,1,1-trikloroetana, delno halogeniranega bromofluoroogljikovodika in bromklorometana.
Each year the Commission is required to determine essential uses for these controlled substances, the quantities that may be used and the companies that may use them.
Vsako leto mora Komisija določiti uporabe bistvenega pomena za te nadzorovane snovi, količine, ki se smejo uporabljati, ter gospodarske družbe, ki jih smejo uporabljati.
Decision IV/25 of the Parties to the Montreal Protocol on Substances that Deplete the Ozone Layer, hereinafter ‘the Montreal Protocol’, sets out the criteria used by the Commission for determining any essential uses and authorises the production and consumption necessary to satisfy essential uses of controlled substances in each Party.
V Sklepu IV/25 pogodbenic Montrealskega protokola o snoveh, ki tanjšajo ozonski plašč, v nadaljnjem besedilu „Montrealski protokol“, so določena merila, ki jih Komisija uporablja za določitev katerih koli uporab bistvenega pomena, in za vsako pogodbenico odobren obseg proizvodnje in porabe nadzorovanih snovi, potreben za uporabe bistvenega pomena.
Decision XV/8 of the Parties to the Montreal Protocol authorises the production and consumption necessary to satisfy essential uses of controlled substances listed in Annexes A, B and C (Group II and III substances) of the Montreal Protocol for laboratory and analytical uses as listed in Annex IV to the report of the Seventh Meeting of the Parties, subject to the conditions set out in Annex II to the report of the Sixth Meeting of the Parties, as well as Decisions VII/11, XI/15 and XV/5 of the Parties to the Montreal Protocol.Decision XVII/10 of the Parties to the Montreal Protocol authorises the production and consumption of the controlled substance listed in Annex E of the Montreal Protocol necessary to satisfy laboratory and analytical uses of methyl bromide.
V Sklepu XV/8 pogodbenic Montrealskega protokola je odobren obseg proizvodnje in porabe nadzorovanih snovi, naštetih v prilogah A, B in C (snovi v skupinah II in III) k Montrealskemu protokolu, ki je potreben za uporabe bistvenega pomena za laboratorijske in analitske namene v skladu s Prilogo IV k Poročilu o sedmem zasedanju pogodbenic, ob upoštevanju pogojev, določenih v Prilogi II k Poročilu o šestem zasedanju pogodbenic, kot tudi sklepov VII/11, XI/15 in XV/5 pogodbenic Montrealskega protokola. V Sklepu XVII/10 pogodbenic Montrealskega protokola je odobren obseg proizvodnje in porabe nadzorovanih snovi, naštetih v Prilogi E k Montrealskemu protokolu, ki je potreben za laboratorijske in analitske uporabe metilbromida.
Pursuant to paragraph 3 of Decision XII/2 of the Parties to the Montreal Protocol on measures to facilitate the transition to chlorofluorocarbon-free Metered-Dose Inhalers (MDIs), all Member States have notified [2] the United Nations Environment Programme that chlorofluorocarbons (CFCs) are no longer essential for the manufacture of salbutamol CFC-MDIs for placing on the market of the European Community.
V skladu z odstavkom 3 Sklepa XII/2 pogodbenic Montrealskega protokola o ukrepih za olajšanje prehoda k inhalatorjem z določenim odmerkom (MDI), ki ne vsebujejo klorofluoroogljikovodika, so vse države članice uradno obvestile [2] Program Združenih narodov za okolje (UNEP), da klorofluoroogljikovodiki (CFC) niso več bistvenega pomena za proizvodnjo CFC-MDI iz salbutamola za dajanje v promet na trg Evropske skupnosti.
Austria, Belgium, Czech Republic, Denmark, Estonia, Germany, Greece, Hungary, Latvia, Lithuania, Norway, Portugal, The Netherlands, the Slovak Republic and Slovenia have notified UNEP that the use of CFCs is not considered essential for the manufacture of MDIs for placing on the market of the European Community that contain the active ingredients belonging to the therapeutic category of ‘short-acting beta agonist bronchiodilators’, specifically terbutaline [3], fenoterol, orciprenaline, reproterol, carbuterol, hexoprenaline, pirbuterol, clenbuterol, bitolterol and procaterol.
Avstrija, Belgija, Češka, Danska, Estonija, Nemčija, Grčija, Madžarska, Latvija, Litva, Norveška, Portugalska, Nizozemska, Slovaška in Slovenija so uradno obvestile UNEP, da se uporaba CFC ne šteje več kot bistvena za proizvodnjo MDI, ki vsebujejo učinkovine v terapevtski kategoriji „kratko delujočih bronhodilatatorjev za doziranje beta-agonista“, natančneje terbutalin [3], fenoterol, orkiprenalin, reproterol, karbuterol, heksoprenalin, pirbuterol, klenbuterol, bitolterol in prokaterol, za dajanje v promet v Evropski skupnosti.
Belgium, the Czech Republic, Estonia, Germany, Hungary, Latvia, the Netherlands, the Slovak Republic, Slovenia and Sweden have notified UNEP that use of CFCs is not considered essential for the manufacture of MDIs for placing on the market of the European Community that contain the active ingredients belonging to the therapeutic category of ‘inhaled steroids’, specifically beclomethasone, dexamethasone, flunisolide, fluticasone, budesonide [4] and triamcinolone.
Belgija, Češka, Estonija, Nemčija, Madžarska, Latvija, Nizozemska, Slovaška, Slovenija in Švedska so uradno obvestile UNEP, da se uporaba CFC ne šteje več kot bistvena za proizvodnjo MDI, ki vsebujejo učinkovine v terapevtski kategoriji „steroidov za inhaliranje“, natančneje beklometazon, deksametazon, flunizolid, flutikazon, budezonid [4] in triamcinolon, za dajanje v promet v Evropski skupnosti.
Denmark (beclomethasone, fluticasone), Ireland (beclomethasone, fluticasone), Finland (beclomethasone, fluticasone), France (beclomethasone, fluticasone), Italy (beclomethasone, fluticasone, budesonide), Malta (fluticasone, budesonide), Portugal (fluticasone, budesonide), Slovenia (beclomethasone, fluticasone, budesonide), Spain (beclomethasone, fluticasone) and the United Kingdom (fluticasone) have notified UNEP that use of CFCs is not considered essential for the manufacture of MDIs for placing on the market of the European Community that contain the active ingredients belonging to the therapeutic category of ‘inhaled steroids’ shown in parentheses after each Member State.
Danska (beklometazon, flutikazon), Irska (beklometazon, flutikazon), Finska (beklometazon, flutikazon), Francija (beklometazon, flutikazon), Italija (beklometazon, flutikazon, budezonid), Malta (flutikazon, budezonid), Portugalska (flutikazon, budezonid), Slovenija (beklometazon, flutikazon, budezonid), Španija (beklometazon, flutikazon) in Združeno kraljestvo (flutikazon) so uradno obvestile UNEP, da se uporaba CFC ne šteje več kot bistvena za proizvodnjo MDI, ki vsebujejo učinkovine iz terapevtske kategorije „steroidov za inhaliranje“, navedene v oklepajih za vsak državo članico, za dajanje v promet v Evropski skupnosti.
Belgium, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Latvia, the Netherlands, the Slovak Republic and Slovenia have notified UNEP that use of CFCs is not considered essential for the manufacture of MDIs for placing on the market of the European Community that contain the active ingredients belonging to the therapeutic category of ‘non-steroidal anti-inflammatories’, specifically cromoglicic acid and nedrocromil.
Belgija, Češka, Danska, Estonija, Finska, Francija, Nemčija, Grčija, Latvija, Nizozemska, Slovaška in Slovenija so uradno obvestile UNEP, da se uporaba CFC ne šteje več kot bistvena za proizvodnjo MDI, ki vsebujejo učinkovine sestavine iz terapevtske kategorije „nesteroidne učinkovine proti vnetjem“, natančneje kromoglikonska kislina in nedrokromil, za dajanje v promet v Evropski skupnosti.
Portugal has notified UNEP that use of CFCs is not considered essential for the manufacture of MDIs for placing on the market of the European Community that contains the active ingredient cromoglicic acid.
Portugalska je uradno obvestila UNEP, da se uporaba CFC ne šteje več kot bistvena za proizvodnjo MDI, ki vsebujejo učinkovino kromoglikonsko kislino, za dajanje v promet v Evropski skupnosti.
Spain has notified UNEP that use of CFCs is not considered essential for the manufacture of MDIs for placing on the market of the European Community that contains the active ingredient nedrocromil.
Španija je uradno obvestila UNEP, da se uporaba CFC ne šteje več kot bistvena za proizvodnjo MDI, ki vsebujejo učinkovino nedrokromil, za dajanje v promet v Evropski skupnosti.
Belgium, Cyprus, the Czech Republic, Denmark, Estonia, Finland, Germany, Greece, Hungary, Ireland, Latvia, Malta, the Netherlands, the Slovak Republic, Spain, Sweden and the United Kingdom have notified UNEP that use of CFCs is not considered essential for the manufacture of MDIs for placing on the market of the European Community that contain the active ingredients belonging to the therapeutic category of ‘anticholinergic bronchodilators’, specifically ipatropium bromide and oxitropium bromide.
Belgija, Ciper, Češka, Danska, Estonija, Finska, Nemčija, Grčija, Madžarska, Irska, Latvija, Malta, Nizozemska, Slovaška, Španija, Švedska in Združeno kraljestvo so uradno obvestili UNEP, da se uporaba CFC ne šteje več kot bistvena za proizvodnjo MDI, ki vsebujejo učinkovine iz terapevtske kategorije „antiholinergičnih bronhodilatatorjev“, natančneje ipratropijev bromid in oksitropijev bromid, za dajanje v promet v Evropski skupnosti.
Portugal has notified UNEP that use of CFCs is not considered essential for the manufacture of MDIs for placing on the market of the European Community that contains the active ingredient ipatropium bromide.
Portugalska je uradno obvestila UNEP, da se uporaba CFC ne šteje več kot bistvena za proizvodnjo MDI, ki vsebujejo učinkovino ipratropijev bromid, za dajanje v promet v Evropski skupnosti.
Germany has notified UNEP that use of CFCs is not considered essential for the manufacture of MDIs for placing on the market of the European Community that contain the active ingredients belonging to the therapeutic category of ‘long-acting beta agonist bronchiodilators’, specifically formoterol and salmeterol.
Nemčija je uradno obvestila UNEP, da se uporaba CFC ne šteje več kot bistvena za proizvodnjo MDI, ki vsebujejo učinkovine iz terapevtskih kategorij „dolgo delujočih bronhodilatatorjev za doziranje beta-agonista“, natančneje formoterol in salmeterol, za dajanje v promet v Evropski skupnosti.
Italy has notified UNEP that use of CFCs is not considered essential for the manufacture of MDIs for placing on the market of the European Community that contains the active ingredient formoterol.
Italija je uradno obvestila UNEP, da se uporaba CFC ne šteje več kot bistvena za proizvodnjo MDI, ki vsebujejo učinkovino formoterol, za dajanje v promet v Evropski skupnosti.
Germany and the Netherlands have notified UNEP that use of CFCs is not considered essential for the manufacture of MDIs for placing on the market of the European Community that contain combinations of active ingredients.
Nemčija in Nizozemska sta uradno obvestili UNEP, da se uporaba CFC ne šteje več kot bistvena za proizvodnjo MDI, ki vsebujejo kombinacije učinkovin, za dajanje v promet v Evropski skupnosti.
These non-essentiality determinations have therefore reduced the demand for CFCs used in MDIs that are placed on the market of the European Community.
Te ugotovitve o nebistvenem pomenu so zmanjšale povpraševanje po CFC za uporabo v MDI, ki se dajejo v promet v Evropski skupnosti.
In addition, Article 4(6) of Regulation (EC) No 2037/2000 prevents CFC-MDI products being imported and placed on the market unless the CFCs in these products are considered essential under the conditions described in Article 3(1).
Poleg tega člen 4(6) Uredbe (ES) št. 2037/2000 preprečuje uvoz in dajanje CFC-MDI v promet, razen v primerih, ko se šteje, da so CFC v teh proizvodih bistvenega pomena v skladu s pogoji, opisanimi v členu 3(1).
The Commission has published a Notice [5] on 8 July 2005 to those companies in the Community of 25 Member States that request consideration by the Commission for the use of controlled substances for essential uses in the Community in 2006 and has received declarations on intended essential uses of controlled substances for 2006.
Komisija je 8. julija 2005 objavila obvestilo [5], naslovljeno na tiste gospodarske družbe v Skupnosti 25 držav članic, ki zahtevajo, da Komisija presodi uporabo nadzorovanih snovi za uporabe bistvenega pomena v Skupnosti v letu 2006, in prejela izjave o nameravanih uporabah nadzorovanih snovi za uporabe bistvenega pomena v letu 2006.
For the purpose of ensuring that interested companies and operators may continue to benefit in due time from the licensing system, it is appropriate that the present decision shall apply from 1 January 2006.
Da lahko zainteresirane gospodarske družbe in izvajalci še naprej pravočasno koristijo sistem izdajanja dovoljenj, je primerno, da se začne ta odločba uporabljati s 1. januarjem 2006.
The measures provided for in this Decision are in accordance with the opinion of the Management Committee established by Article 18(1) of Regulation (EC) No 2037/2000,
Ukrepi, predvideni s to odločbo, so skladni z mnenjem Upravljalnega odbora, ustanovljenega s členom 18(1) Uredbe (ES) št. 2037/2000 –
The quantity of controlled substances of Group I (chlorofluorocarbons 11, 12, 113, 114 and 115) subject to Regulation (EC) No 2037/2000 which may be used for essential medical uses in the Community in 2006 shall be 539000,00 ODP [6] kilograms.
Količina nadzorovanih snovi skupine I (klorofluoroogljikovodikov 11, 12, 113, 114 in 115) v skladu z Uredbo (ES) št. 2037/2000, ki se sme uporabljati za bistvene medicinske uporabe v Skupnosti v letu 2006, je 539000,00 kilogramov ODP [6].
The quantity of controlled substances of Group I (chlorofluorocarbons 11, 12, 113, 114 and 115) and Group II (other fully halogenated chlorofluorocarbons) subject to Regulation (EC) No 2037/2000 which may be used for essential laboratory uses in the Community in 2006 shall be 256761,86 ODP kilograms.
Količina nadzorovanih snovi skupine I (klorofluoroogljikovodikov 11, 12, 113, 114 in 115) in skupine II (drugih popolnoma halogeniranih klorofluoroogljikovodikov) v skladu z Uredbo (ES) št. 2037/2000, ki se sme uporabljati za bistvene laboratorijske uporabe v Skupnosti v letu 2006, je 256761,86 kilogramov ODP.
The quantity of controlled substances of Group III (halons) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory use in the Community in 2006 shall be 482,70 ODP kilograms.
Količina nadzorovanih snovi skupine III (halonov) v skladu z Uredbo (ES) št. 2037/2000, ki se sme uporabljati za bistvene laboratorijske uporabe v Skupnosti v letu 2006, je 482,70 kilogramov ODP.
The quantity of controlled substances of Group IV (carbon tetrachloride) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the Community in 2006 shall be 149641,536 ODP kilograms.
Količina nadzorovanih snovi skupine IV (ogljikovega tetraklorida) v skladu z Uredbo (ES) št. 2037/2000, ki se sme uporabljati za bistvene laboratorijske uporabe v Skupnosti v letu 2006, je 149641,536 kilogramov ODP.
The quantity of controlled substances of Group V (1,1,1-trichloroethane) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the European Union in 2006 shall be 754,00 ODP kilograms.
Količina nadzorovanih snovi skupine V (1,1,1-trikloroetana) v skladu z Uredbo (ES) št. 2037/2000, ki se sme uporabljati za bistvene laboratorijske uporabe v Evropski uniji v letu 2006, je 754,00 kilogramov ODP.
The quantity of controlled substances of Group VI (methyl bromide) subject to Regulation (EC) No 2037/2000 that may be used for laboratory and analytical uses in the Community in 2006 shall be 300,00 ODP kilograms.
Količina nadzorovanih snovi skupine VI (metilbromida) v skladu z Uredbo (ES) št. 2037/2000, ki se sme uporabljati za laboratorijske in analitske uporabe v Skupnosti v letu 2006, je 300,00 kilogramov ODP.
The quantity of controlled substances of Group VII (hydrobromofluorocarbons) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the Community in 2006 shall be 4,49 ODP kilograms.
Količina nadzorovanih snovi skupine VII (delno halogeniranih bromofluoroogljikovodikov) v skladu z Uredbo (ES) št. 2037/2000, ki se sme uporabljati za bistvene laboratorijske uporabe v Skupnosti v letu 2006, je 4,49 kilogramov ODP.
The quantity of controlled substances of group IX (bromochloromethane) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the Community in 2006 shall be 13,308 ODP kilograms.
Količina nadzorovanih snovi skupine IX (bromoklorometana) v skladu z Uredbo (ES) št. 2037/2000, ki se sme uporabljati za bistvene laboratorijske uporabe v Skupnosti v letu 2006, je 13,308 kilogramov ODP.
The chlorofluorocarbon metered-dose inhalers listed in Annex I shall not be placed on markets where the Competent Authority has determined chlorofluorocarbonsfor metered-dose inhalers on those markets to be non-essential.
Inhalatorji z določenim odmerkom, ki vsebujejo klorofluoroogljikovodik, navedeni v Prilogi I, se ne dajo v promet na trge, če je pristojni organ ugotovil, da klorofluoroogljikovodiki za inhalatorje z določenim odmerkom na navedenih trgih niso bistvenega pomena.
During the period 1 January to 31 December 2006 the following rules shall apply:
Med obdobjem od 1. januarja do 31. decembra 2006 se uporabljajo naslednja pravila:
The allocation of essential medical use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115 shall be to the companies indicated in Annex II.
Kvote klorofluoroogljikovodikov 11, 12, 113, 114 in 115 za bistvene medicinske uporabe se dodelijo gospodarskim družbam, navedenim v Prilogi II.
The allocation of essential laboratory use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115 and other fully halogenated chlorofluorocarbons shall be to the companies indicated in Annex III.
Kvote klorofluoroogljikovodikov 11, 12, 113, 114 in 115 in drugih popolnoma halogeniranih klorofluoroogljikovodikov za bistvene laboratorijske uporabe se dodelijo gospodarskim družbam, navedenim v Prilogi III.
The allocation of essential laboratory use quotas for halons shall be to the companies indicated in Annex IV.
Kvote halonov za bistvene medicinske uporabe se dodelijo gospodarskim družbam, navedenim v Prilogi IV.
The allocation of essential laboratory use quotas for carbon tetrachloride shall be to the companies indicated in Annex V.
Kvote ogljikovega tetraklorida za bistvene laboratorijske uporabe se dodelijo gospodarskim družbam, navedenim v Prilogi V.
The allocation of essential laboratory use quotas for 1,1,1-trichloroethane shall be to the companies indicated in Annex VI.
Kvote 1,1,1-trikloroetana za bistvene laboratorijske uporabe se dodelijo gospodarskim družbam, navedenim v Prilogi VI.